Research programme: tuberculosis peptide vaccine - EpiVax/Sequella/Valneva

Drug Profile

Research programme: tuberculosis peptide vaccine - EpiVax/Sequella/Valneva

Alternative Names: Peptide TB vaccine - Sequella; TB peptide vaccine - Sequella

Latest Information Update: 02 Jul 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator EpiVax; Intercell; Sequella
  • Developer Sequella
  • Class Antituberculars; Peptide vaccines; Peptides; Tuberculosis vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Tuberculosis

Most Recent Events

  • 02 Jul 2013 No development reported - Preclinical for Tuberculosis in USA (unspecified route)
  • 28 May 2013 Intercell has merged with Vivalis to form Valneva
  • 24 Oct 2001 Preclinical development for Tuberculosis in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top